STOCKHOLM, Sweden, April 9, 2026. KDventures AB (Nasdaq Stockholm: KDV) today announces that its portfolio company SVF Vaccines has entered into a collaboration with Touchlight, a biotechnology company specializing in cell-free DNA manufacturing. The purpose of the collaboration is to accelerate SVF Vaccines’ lead hepatitis B/D immunotherapy program, SVF-001, toward clinical development.
SVF-001 represents a novel approach designed to induce both neutralizing antibody responses and T‑cell responses against key viral targets. Under the collaboration, SVF Vaccines and Touchlight will work together to support the use of Touchlight’s proprietary doggybone DNA™ (dbDNA™) platform, a cell-free DNA technology designed to enable rapid, scalable and high-purity DNA manufacturing. The collaboration is expected to support an efficient path forward as SVF Vaccines advances SVF-001 and prepares the program for the next stage of development.
“The collaboration between our portfolio company SVF Vaccines and Touchlight is a strategically important step in the efforts to expeditiously and efficiently bring the unique hepatitis B/D immunotherapy candidate SVF-001 towards clinical development,” comments Viktor Drvota, CEO of KDventures.
KDventures holds a direct ownership in SVF Vaccines of 33 percent.